企業プロフィール · Healthcare

Amgen Inc

AMGN · 米国株
取引所
米国株
国 / 地域
USA
上場日
1983年6月17日
従業員数
31,500
公式サイト
www.amgen.com
現在値
$337.6
リアルタイム · 2026年6月18日
ベイリー成長スコア
43/100
やや弱い
本源的価値 · 3 段階レンジ 現在値 $337.6 リアルタイム · 楽観的な本源的価値レンジ内 · 多くの期待を織り込み済み

総合バリュエーションレンジ · 保守的 $200–$250 / 妥当 $260–$320 / 楽観的 $320–$380。$337.6 時点で 楽観的な本源的価値レンジ内 · 多くの期待を織り込み済み。

レポート公開時 $331.57(2026年5月21日)

この銘柄のレポートはお使いの言語でまだありません。

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is he

時価総額$1843.97億
売上高(TTM)$372.2億
EBITDA$169.18億
純利益率20.96%
ROE101.32%
PER (TTM)23.78
予想PER15.36
PEG2.26
EPS$14.37
配当利回り2.78%
52週レンジ$260.01 – $388.36
アナリスト目標株価$352.77
アナリスト評価3.6 / 5

データ提供:EODHD、報告通貨で表示。参考情報であり、投資助言ではありません。

沿革

近日公開このセクションは現在準備中です。近日公開予定です。

業界での地位

近日公開このセクションは現在準備中です。近日公開予定です。